Harmacol. 2011;254:267?9. Tannock IF, de Wit R, Berry WR, et al. Docetaxel

Lancet. 2010;376:1147?4. Quach JM, Askmyr M, Jovic T, et al. Myelosuppressive therapies drastically improve pro-inflammatory cytokines and directly bring about bone loss. J Bone Miner Res. 2014; doi: 10.1002/jbmr.2415. This study discovered that myelosuppresive chemotherapies directly cause bone loss. Shandala T, Shen NY, Hopwood B, et al. The part of osteocyte apoptosis in cancer chemotherapy-induced bone loss. J Cell Physiol. 2012;227:2889?7. Georgiou KR, King TJ, Scherer MA, et al. Attenuated Wnt/betacatenin signalling mediates methotrexate chemotherapy-induced bone loss and marrow adiposity in rats. Bone. 2012;50:1223?three. Tipples K, Robinson A. Optimal management of cancer treatmentinduced bone loss: considerations for elderly patients. Drugs Aging. 2011;28:867?three. Canalis E, Delany AM. Mechanisms of glucocorticoid action in bone. Ann N Y Acad Sci. 2002;966:73?1. Williams HJ, Davies AM. The impact of X-rays on bone: a pictorial review. Eur Radiol. 2006;16:619?three. Matsumura S, Jikko A, Hiranuma H, et al. Effect of X-ray irradiation on proliferation and differentiation of osteoblast. Calcif Tissue Int. 1996;59:307?. Szymczyk KH, Shapiro IM, Adams CS. Ionizing radiation sensitizes bone cells to apoptosis. Bone. 2004;34:148?six. Chandra A, Lin T, Tribble MB, et al. PTH1-34 alleviates radiotherapy-induced regional bone loss by improving osteoblast and osteocyte survival.Harmacol. 2011;254:267?9. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502?2. de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing SB856553 biological activity following docetaxel remedy: a randomised open-label trial. Lancet. 2010;376:1147?4. Quach JM, Askmyr M, Jovic T, et al. Myelosuppressive therapies substantially boost pro-inflammatory cytokines and directly lead to bone loss. J Bone Miner Res. 2014; doi: ten.1002/jbmr.2415. This study discovered that myelosuppresive chemotherapies straight result in bone loss. Shandala T, Shen NY, Hopwood B, et al. The function of osteocyte apoptosis in cancer chemotherapy-induced bone loss. J Cell Physiol. 2012;227:2889?7. Georgiou KR, King TJ, Scherer MA, et al. Attenuated Wnt/betacatenin signalling mediates methotrexate chemotherapy-induced bone loss and marrow adiposity in rats. Bone. 2012;50:1223?3. Tipples K, Robinson A. Optimal management of cancer treatmentinduced bone loss: considerations for elderly sufferers. Drugs Aging. 2011;28:867?three. Canalis E, Delany AM. Mechanisms of glucocorticoid action in bone. Ann N Y Acad Sci. 2002;966:73?1. Williams HJ, Davies AM. The impact of X-rays on bone: a pictorial review. Eur Radiol. 2006;16:619?three. Matsumura S, Jikko A, Hiranuma H, et al. Impact of X-ray irradiation on proliferation and differentiation of osteoblast. Calcif Tissue Int. 1996;59:307?. Szymczyk KH, Shapiro IM, Adams CS. Ionizing radiation sensitizes bone cells to apoptosis. Bone. 2004;34:148?six. Chandra A, Lin T, Tribble MB, et al. PTH1-34 alleviates radiotherapy-induced neighborhood bone loss by improving osteoblast and osteocyte survival. Bone. 2014;67:33?0. Gives a summary of studies within the introduction concerning radiotherapy-induced alterations in osteoclast number and activity. Indicates that PTH1-34 might alleviate radiotherapy-induced bone loss by enhancing osteoblast and osteocyte survival.